Navigation Links
Debiopharm and EPFL Sign Research Project Agreement to Identify Inhibitors of Signalling Pathways Controlling Cell Fate for Cancer Treatment
Date:9/2/2008

LAUSANNE, Switzerland, September 2 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist focusing on serious medical conditions and particularly oncology, today announced the signature of a research project with the Ecole Polytechnique Federale de Lausanne (EPFL), aimed at the identification of novel small molecules and peptides that interfere with pathways controlling cell fate specification. The project, named Debio 0826, could lead to the development of potential therapeutic compounds and to the identification of new targets to fight cancer stem cells.

Following the signature of an EPFL-Debiopharm partnership on February 12, this first joint research project will be performed under the supervision of Dr. Freddy Radtke, Associate Professor at the Swiss Institute for Experimental Cancer Research (ISREC) and Dr. Gerardo Turcatti, MER, Director of the Biomolecular Screening Facility (BSF), two groups at the EPFL. Debio 0826 will benefit from the multiple molecular and genetic tools generated by Dr. Radtke's group over the past 10 years, as well as the expertise of Dr. Turcatti in the molecular screening field.

"Targeting pathways controlling cell fate specification could generate innovative anti-cancer drugs with anti-tumoural, anti-metastatic and anti-angiogenic properties to treat tumours that are currently resistant to standard therapies," said Kamel Besseghir, CEO of Debiopharm S.A.

About Debiopharm Group

Debiopharm Group is a global biopharmaceutical development specialist that in-licenses promising biologics and small molecule drug candidates. Debiopharm develops its products for global registration and maximum commercial potential for out-licensing to pharmaceutical partners for sales and marketing. Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

Founded in 1979 and headquartered in Lausanne, Switzerland, Debiopharm has developed three products with global combined sales in excess of $2.65 billion in 2007.

For more information on Debiopharm Group, please visit: http://www.debiopharm.com.

Debiopharm S.A. Contacts

Andres McAllister

Chief Scientific Officer

Tel.: +41(0)21-321-01-11

Fax: +41(0)21-321-01-69

amcallister@debiopharm.com

Additional Media Contacts

In London

Maitland

Brian Hudspith

Tel: +44(0)20-7379-5151

bhudspith@maitland.co.uk

In New York

Russo Partners, LLC

Wendy Lau

Tel: +1-212-845-4272

Fax: +1-212-845-4260

wendy.lau@russopartnersllc.com


'/>"/>
SOURCE Debiopharm Group
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
3. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
4. Researchers at Cleveland Clinic Identify Site of Dysfunction in HDL, Carrier of Good Cholesterol
5. Video: New Research Discovers Independent Brain Networks Control Human Walking
6. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
7. Cleveland Clinic Researchers Identify Mechanism Behind Platelet Function and Potentially Fatal Blood Clot Formation
8. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
9. Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells
10. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
11. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... February 20, 2017 According to a new market ... Dry powder), Device Type (Metered dose, Dry Powder, Nebulizer)), Canister (Plain, Coated), ... MarketsandMarkets, The market is projected to reach USD 52.37 Billion by 2021 ... the forecast period. Continue Reading ... ...
(Date:2/20/2017)... , February 20, 2017 Acute, Chronic and ... expected to grow at a CAGR of 7% from 2016-2021 and CAGR ... CAGR of 6% from 2016 to 2027. The market is estimated at ... ... Read on to discover how you can exploit the future business opportunities ...
(Date:2/19/2017)... Fla. , Feb. 18, 2017 Nektar ... positive Phase 1 clinical data for Nektar,s lead immuno-oncology ... were presented at ASCO GU 2017.  NKTR-214 is an ... cells and Natural Killer (NK) cell abundance directly in ... these immune cells.  The results were presented by ...
Breaking Medicine Technology:
(Date:2/20/2017)... (PRWEB) , ... February 20, 2017 , ... ... eye care providers and health plan partners, announced during the 2017 Annual ... success enhancing care coordination for diabetic patients and integrating eye care into ...
(Date:2/19/2017)... ... , ... ProBrand Glitch is a set of 30 glitch distortion logo reveals made exclusively for ... logo with a glitch reveal in just a few clicks of a mouse. Customizable glitch ... each preset. Use these presets to add a uniquely animated logo to any photos or ...
(Date:2/18/2017)... ... February 17, 2017 , ... ... disruptive innovation in the industry, according to the recent NEJM Catalyst Insights Report ... surveys of the NEJM Catalyst Insights Council, a qualified group of U.S. executives, ...
(Date:2/18/2017)... ... February 18, 2017 , ... ... Pixel Film Studios ’ ProParagraph Fashion Volume 2 for all multi-line FCPX ... applications. Users can pick and choose from hand-crafted trend-setting designs with smooth ...
(Date:2/17/2017)... ... February 17, 2017 , ... The Alliance Healthcare Foundation (AHF) ... further positively impact the health and wellness of our community in San Diego ... duty to seriously consider releasing our assets beyond our 5% targeted distribution each ...
Breaking Medicine News(10 mins):